Developing standardized corticosteroid treatment for Duchenne muscular dystrophy

Michela Guglieri, Kate Bushby, Michael P. McDermott, Kimberly A. Hart, Rabi Tawil, William B. Martens, Barbara E. Herr, Elaine McColl, Jennifer Wilkinson, Janbernd Kirschner, Wendy M. King, Michele Eagle, Mary W. Brown, Tracey Willis, Deborah Hirtz, Perry B. Shieh, Volker Straub, Anne Marie Childs, Emma Ciafaloni, Russell J. ButterfieldIain Horrocks, Stefan Spinty, Kevin M. Flanigan, Nancy L. Kuntz, Giovanni Baranello, Helen Roper, Leslie Morrison, Jean K. Mah, Adnan Y. Manzur, Craig M. McDonald, Ulrike Schara, Maja von der Hagen, Richard J. Barohn, Craig Campbell, Basil T. Darras, Richard S. Finkel, Giuseppe Vita, Imelda Hughes, Tiziana Mongini, Elena Pegoraro, Matthew Wicklund, Ekkehard Wilichowski, W. Bryan Burnette, James F. Howard, Hugh J. McMillan, Mathula Thangarajh, Robert C. Griggs

Research output: Contribution to journalArticle

Abstract

Despite corticosteroids being the only treatment documented to improve strength and function in boys with Duchenne muscular dystrophy (DMD) corticosteroid prescription is inconsistent and in some countries, corticosteroids are not prescribed. We are conducting a clinical trial that (1) compares the 3 most frequently prescribed corticosteroid regimes; (2) standardizes treatment of DMD complications; and (3) standardizes prevention of corticosteroid side effects. Investigators at 38 sites in 5 countries plan to recruit 300 boys aged 4–7 who are randomly assigned to one of three regimens: daily prednisone; daily deflazacort; or intermittent prednisone (10 days on/10 days off). Boys are followed for a minimum of 3 years to assess the relative effectiveness and adverse event profiles of the different regimens. The primary outcome is a 3-dimensional variable consisting of log-transformed time to rise from the floor, forced vital capacity, and subject/parent satisfaction with treatment, each averaged over all post-baseline visits. The study protocol includes evidence- and consensus-based treatment of DMD complications and of corticosteroid side effects. This study seeks to establish a standard corticosteroid regimen for DMD. Since all new interventions for DMD are being developed as add-on therapies to corticosteroids, defining the optimum regimen is of importance for all new treatments.

Original languageEnglish
Pages (from-to)34-39
Number of pages6
JournalContemporary Clinical Trials
Volume58
DOIs
Publication statusPublished - Jul 1 2017

    Fingerprint

Keywords

  • Deflazacort
  • Duchenne muscular dystrophy
  • Prednisolone
  • Randomized
  • Standards of care

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Guglieri, M., Bushby, K., McDermott, M. P., Hart, K. A., Tawil, R., Martens, W. B., Herr, B. E., McColl, E., Wilkinson, J., Kirschner, J., King, W. M., Eagle, M., Brown, M. W., Willis, T., Hirtz, D., Shieh, P. B., Straub, V., Childs, A. M., Ciafaloni, E., ... Griggs, R. C. (2017). Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemporary Clinical Trials, 58, 34-39. https://doi.org/10.1016/j.cct.2017.04.008